PCH
PTGX icon

Polar Capital Holdings’s Protagonist Therapeutics PTGX Stock Holding History

Polar Capital Holdings’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-350,000
Closed -$13.5M – 311
2024
Q4 		$13.5M Hold
350,000
– – 0.08% 178
2024
Q3 		$15.8M Buy
+350,000
New +$14.1M 0.08% 163
2022
Q2 		– Sell
-303,429
Closed -$7.18K – 465
2022
Q1 		$7.18K Hold
303,429
– – 0.03% 243
2021
Q4 		$10.4K Buy
303,429
+84,493
+39% +$2.67M 0.04% 228
2021
Q3 		$3.88K Buy
218,936
+99,733
+84% +$4.25M 0.02% 288
2021
Q2 		$5.35K Buy
+119,203
New +$3.93M 0.02% 272

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Polar Capital Holdings's PTGX Position: Q1 2025 in Review

Polar Capital Holdings sold out of Protagonist Therapeutics (PTGX) in Q1 2025, closing a stake of 350,000 shares — an estimated $13.5M sold.

Polar Capital Holdings first reported a position in PTGX in Q2 2021 and held it in 6 quarters. The position peaked at $15.8M in Q3 2024. 275 funds tracked by Wall St. Rank hold PTGX as of Q1 2025.

  • Polar Capital Holdings reported no remaining Protagonist Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Polar Capital Holdings sold 350,000 Protagonist Therapeutics shares in Q1 2025, an estimated $13.5M.
  • Polar Capital Holdings first reported a position in Protagonist Therapeutics in Q2 2021 and held it in 6 quarters.
  • Polar Capital Holdings's Protagonist Therapeutics position peaked at $15.8M in Q3 2024.
  • 275 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2025.

Based on Polar Capital Holdings's 13F filing for Q1 2025, filed 15 May 2025.